Key Takeaways
- Infinitopes is developing ITOP1, an off-the-shelf cancer vaccine targeting tumor antigens to elicit immune responses.
- ITOP1 integrates into standard perioperative care, potentially preventing cancer recurrence after surgery.
- The company navigates a challenging landscape for therapeutic cancer vaccines, aiming to establish ITOP1’s efficacy in early intervention.
Infinitopes’ Innovative Cancer Vaccine Approach
Infinitopes is pioneering a novel method for cancer vaccine development by targeting specific antigens displayed by tumors to the immune system. Their platform employs immunopeptidomics, using mass spectrometry to identify peptides presented on HLA (Human Leukocyte Antigen) molecules. Computational techniques then prioritize these antigens based on their potential relevance across different patients.
The company’s lead candidate, ITOP1, is designed as a precision vaccine that aims to trigger CD8+ cytotoxic T-cell responses against tumor antigens. One of the distinguishing aspects of ITOP1 is its integration into standard perioperative care. The vaccine follows a prime-boost schedule in conjunction with chemotherapy and surgery, directing the immune system’s focus towards any residual disease following tumor resection. This approach positions ITOP1 as a preventive strategy against recurrence rather than a last-resort treatment, enabling Infinitopes to evaluate whether immune priming has tangible clinical effects.
The landscape for therapeutic cancer vaccines has been historically mixed, marked by numerous late-stage clinical disappointments. However, recent advancements have reignited interest in the field. Notably, Moderna and Merck reported that their personalized mRNA vaccine, combined with Keytruda, reduced recurrence or mortality risk by 49% in patients with high-risk melanoma over five years.
Currently, two main design strategies dominate the cancer vaccine space. The personalized neoantigen approach tailors vaccines to individual patients’ tumor-specific mutations, posing challenges in scalability. In contrast, off-the-shelf or shared-antigen strategies, like those employed by Infinitopes, utilize fixed antigen sets applicable to a broader patient population. ITOP1 exemplifies this latter approach, leveraging antigens derived from what tumors present to the immune system.
While Infinitopes is focused on the off-the-shelf segment, it faces competition from other companies, including BioNTech and Nouscom. BioNTech’s BNT111, although it has shown promise, has been discontinued, yet its FixVac platform continues with other candidates. Nouscom’s NOUS-209, which targets shared neoantigens in microsatellite-instability tumors, provides a point of comparison for Infinitopes’ strategy.
The landscape remains fraught with risks and rewards in the off-the-shelf cancer vaccine segment. Setbacks in late-stage trials often lead to significant adjustments, as evidenced by IO Biotech’s recent challenges. The pivotal question for Infinitopes is whether its precision vaccine can demonstrate a sustained clinical impact when utilized earlier in the treatment process.
The content above is a summary. For more details, see the source article.